Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 25 studies | 35% ± 11% | |
| astrocyte | 16 studies | 34% ± 19% | |
| macrophage | 15 studies | 35% ± 16% | |
| microglial cell | 13 studies | 47% ± 12% | |
| oligodendrocyte | 13 studies | 38% ± 14% | |
| oligodendrocyte precursor cell | 12 studies | 32% ± 14% | |
| fibroblast | 12 studies | 28% ± 8% | |
| mast cell | 10 studies | 30% ± 10% | |
| epithelial cell | 9 studies | 32% ± 14% | |
| adipocyte | 9 studies | 37% ± 12% | |
| glutamatergic neuron | 8 studies | 42% ± 25% | |
| B cell | 8 studies | 27% ± 9% | |
| pericyte | 8 studies | 23% ± 7% | |
| GABAergic neuron | 7 studies | 42% ± 22% | |
| dendritic cell | 7 studies | 30% ± 5% | |
| myeloid cell | 7 studies | 33% ± 9% | |
| endothelial cell of lymphatic vessel | 7 studies | 43% ± 11% | |
| type I pneumocyte | 6 studies | 25% ± 8% | |
| type II pneumocyte | 6 studies | 29% ± 8% | |
| smooth muscle cell | 6 studies | 23% ± 7% | |
| neuron | 5 studies | 37% ± 24% | |
| cardiac muscle cell | 5 studies | 51% ± 14% | |
| ciliated cell | 5 studies | 25% ± 7% | |
| natural killer cell | 5 studies | 21% ± 5% | |
| monocyte | 5 studies | 34% ± 8% | |
| basal cell | 5 studies | 34% ± 14% | |
| classical monocyte | 4 studies | 20% ± 3% | |
| non-classical monocyte | 4 studies | 22% ± 5% | |
| granule cell | 4 studies | 21% ± 3% | |
| retina horizontal cell | 4 studies | 24% ± 8% | |
| retinal cone cell | 4 studies | 27% ± 11% | |
| CD4-positive, alpha-beta T cell | 4 studies | 20% ± 2% | |
| CD8-positive, alpha-beta T cell | 4 studies | 17% ± 2% | |
| mesothelial cell | 4 studies | 30% ± 9% | |
| lymphocyte | 4 studies | 28% ± 7% | |
| retinal rod cell | 4 studies | 32% ± 8% | |
| T cell | 4 studies | 27% ± 5% | |
| club cell | 4 studies | 32% ± 10% | |
| interneuron | 4 studies | 49% ± 24% | |
| conventional dendritic cell | 3 studies | 28% ± 9% | |
| GABAergic interneuron | 3 studies | 20% ± 2% | |
| glial cell | 3 studies | 21% ± 2% | |
| plasma cell | 3 studies | 28% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 19% ± 2% | |
| mononuclear phagocyte | 3 studies | 32% ± 9% | |
| vein endothelial cell | 3 studies | 39% ± 20% | |
| Mueller cell | 3 studies | 31% ± 11% | |
| amacrine cell | 3 studies | 24% ± 8% | |
| regulatory T cell | 3 studies | 17% ± 1% | |
| endothelial cell of vascular tree | 3 studies | 37% ± 16% | |
| hepatocyte | 3 studies | 58% ± 15% | |
| retinal pigment epithelial cell | 3 studies | 31% ± 14% | |
| connective tissue cell | 3 studies | 23% ± 7% | |
| ependymal cell | 3 studies | 29% ± 14% | |
| megakaryocyte-erythroid progenitor cell | 3 studies | 26% ± 6% | |
| alveolar macrophage | 3 studies | 42% ± 12% | |
| capillary endothelial cell | 3 studies | 29% ± 4% | |
| respiratory goblet cell | 3 studies | 33% ± 13% | |
| goblet cell | 3 studies | 37% ± 25% | |
| transit amplifying cell | 3 studies | 34% ± 19% | |
| leukocyte | 3 studies | 40% ± 9% | |
| plasmacytoid dendritic cell | 3 studies | 26% ± 5% | |
| mural cell | 3 studies | 33% ± 10% | |
| mucus secreting cell | 3 studies | 33% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 1090.60 | 459 / 459 | 100% | 37.30 | 1118 / 1118 |
| esophagus | 100% | 860.61 | 1445 / 1445 | 100% | 16.20 | 183 / 183 |
| ovary | 100% | 906.30 | 180 / 180 | 100% | 22.60 | 430 / 430 |
| prostate | 100% | 1075.00 | 245 / 245 | 100% | 34.69 | 502 / 502 |
| kidney | 100% | 1251.10 | 89 / 89 | 100% | 31.62 | 900 / 901 |
| lung | 100% | 889.64 | 577 / 578 | 100% | 25.18 | 1155 / 1155 |
| brain | 100% | 619.90 | 2634 / 2642 | 100% | 29.90 | 705 / 705 |
| adrenal gland | 100% | 1229.13 | 258 / 258 | 100% | 32.60 | 229 / 230 |
| thymus | 100% | 1225.08 | 653 / 653 | 100% | 32.85 | 602 / 605 |
| stomach | 100% | 827.70 | 359 / 359 | 99% | 23.67 | 284 / 286 |
| uterus | 100% | 964.24 | 170 / 170 | 99% | 21.50 | 454 / 459 |
| pancreas | 100% | 599.80 | 328 / 328 | 99% | 20.76 | 176 / 178 |
| intestine | 100% | 905.99 | 966 / 966 | 98% | 27.30 | 519 / 527 |
| bladder | 100% | 999.67 | 21 / 21 | 98% | 23.63 | 493 / 504 |
| liver | 100% | 561.93 | 226 / 226 | 97% | 16.76 | 395 / 406 |
| skin | 100% | 781.15 | 1806 / 1809 | 94% | 23.48 | 446 / 472 |
| adipose | 100% | 1037.53 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 941.62 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 31.41 | 29 / 29 |
| spleen | 100% | 983.68 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 16.49 | 45 / 45 |
| muscle | 99% | 500.57 | 796 / 803 | 0% | 0 | 0 / 0 |
| heart | 98% | 938.13 | 848 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 86% | 490.07 | 801 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 81% | 12.97 | 65 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005515 | Molecular function | protein binding |
| Gene name | COMMD10 |
| Protein name | Alternative protein COMMD10 COMM domain containing 10 COMM domain-containing protein 10 |
| Synonyms | hCG_36808 HSPC305 PTD002 |
| Description | FUNCTION: May modulate activity of cullin-RING E3 ubiquitin ligase (CRL) complexes . May down-regulate activation of NF-kappa-B . . |
| Accessions | L8EAU8 H0Y9N4 ENST00000506589.1 ENST00000632434.1 D6RC04 ENST00000507356.5 ENST00000274458.9 ENST00000515539.5 D6RJ90 Q9Y6G5 |